Back to Freepaper Session

The AcrySof Cachet phakic intraocular lens for correction of moderate to high myopia: 12-month follow-up

Session Details

Session Title: Phakic IOL Implantation I

Session Date/Time: Tuesday 08/10/2013 | 14:00-16:00

Paper Time: 14:30

Venue: Main Lecture Hall (Ground Floor)

First Author: : N.Franqueira PORTUGAL

Co Author(s): :    T. Monteiro   R. Leite   F. Vaz        

Abstract Details

Purpose:

To evaluate the safety and effectiveness of the angle supported phakic intraocular lens (pIOL) Acrysof Cachet (Alcon Laboratories, Inc., Fort Worth, TX) for correction of moderate to high myopia.

Setting:

Department of Ophthalmology, Braga hospital; Braga, Portugal

Methods:

A total of 31 consecutive eyes implanted with the Acrysof Cachet pIOL for the correction of myopia were included in the study. All eyes had a minimum follow-up of 12 months. Outcome measures included uncorrected visual acuity (UCVA) and best spectacle corrected visual acuity (BSCVA) pre and postoperative, mean manifest refraction spherical equivalent (MRSE) pre and postoperative, endothelial cell counts pre and postoperative and adverse events.

Results:

A total of 31 eyes were analysed. The overall preoperative MRSE was -9,07D (range: -5,75D to -16D). Mean postoperative UCVA was 0,89 ± 0,22; mean postoperative BSCVA was 0,98 ± 0,15. Postoperative mean spherical equivalent was -0,41D. Residual refractive error was within +/- 1,00D in 94% of the eyes and within +/- 0,50D in 75% of the eyes. No subjects lost lines of BSCVA. The overall mean percentage change in central endothelial cell density 12 months after surgery was -3,71 ± 0,82 %. No pupillary block, pupil ovalization, corneal decompensation or retinal detachment were observed. In the immediate postoperative period we observed one case of ocular hypertension and one case of anterior uveitis, both successfully treated with topical medications.

Conclusions:

The Acrysof Cachet angle-supported phakic IOL provided favorable refractive correction and predictability and acceptable safety in eyes with moderate to high myopia.

Financial Interest:

NONE